Publicaciones en colaboración con investigadores/as de Novartis (Sweden) (3)

2017

  1. Secukinumab demonstrates greater sustained improvements in daily activities and personal relationships than ustekinumab in patients with moderate-to-severe plaque psoriasis: 52-week results from the CLEAR study

    Journal of the European Academy of Dermatology and Venereology, Vol. 31, Núm. 10, pp. 1693-1699

  2. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate-to-severe plaque psoriasis up to 1 year: Results from the CLEAR study

    Journal of the American Academy of Dermatology, Vol. 76, Núm. 1, pp. 60-69.e9

2015

  1. Secukinumab is superior to ustekinumab in clearing skin of subjects with moderate to severe plaque psoriasis: CLEAR, a randomized controlled trial

    Journal of the American Academy of Dermatology, Vol. 73, Núm. 3, pp. 400-409